Trial Profile
A Phase I, Open Label Study to Evaluate the Safety, Tolerability and Immunogenicity of PENNVAX-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV clade B DNA vaccine Inovio (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 06 Jan 2015 Results published in an Inovio Pharmaceuticals media release and in the journal Molecular Therapy.
- 13 Mar 2012 Interim results published in an Inovio Pharmaceuticals media release.
- 09 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.